In contrast to our results, a high ESR1 expression was a strong predictor of tamoxifen benefits in ER+ breast cancer in the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 trial [16]. Here, ESR1 is linked to breast carcinoma.